Misplaced Pages

Carmen Puliafito

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

This is an old revision of this page, as edited by Fuzheado (talk | contribs) at 21:02, 17 July 2017 (copy edits). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 21:02, 17 July 2017 by Fuzheado (talk | contribs) (copy edits)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)
Carmen A. Puliafito

Carmen A. Puliafito is an American ophthalmologist and former dean of the University of Southern California medical school, the Keck School of Medicine.

Career

Puliafito was born in Buffalo, New York. He received a degree in medicine from Harvard Medical School and completed a residency in ophthalmology and a fellowship in vitreoretinal surgery at Massachusetts Eye and Ear Infirmary. Additionally, he completed an MBA from the Wharton School of the University of Pennsylvania.

Dr. Puliafito was chair of the Department of Ophthalmology at Tufts University School of Medicine from 1991 to 2001. From 2001 to 2007 he was director of the Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine, and chair of the department of ophthalmology. Puliafito was appointed dean of USC's Keck school in December 2007. In 2012 he was 21st of the most highly-paid research university executives in the United States. In March 2016, Puliafito resigned as dean and USC professor Rohit Varma was appointed interim dean.

He has served on the board of the Children's Hospital Los Angeles.

Research

Puliafito was one of the inventors of optical coherence tomography (OCT); for this work, James Fujimoto, Eric Swanson and Puliafito received a Rank Prize for Opto-electronics in 2002. In 2012 Fujimoto, Swanson and David Huang, with Puliafito and Joel Schuman, received an António Champalimaud Vision Award from the Champalimaud Foundation.

Puliafito participated in research into the use of bevacizumab for the treatment of retinal disorders.

Controversy

The Los Angeles Times reported in a July 17, 2017 expose that while Pulafito served as dean and USC professor, he "kept company with a circle of criminals and drug users who said he used methamphetamine and other drugs with them." Three weeks before resigning as dean, a 21-year-old prostitute (as reported by the Los Angeles Times) had overdosed in his presence in a Pasadena hotel room. The LA Times reported that police found methamphetamine in the hotel room.

References

  1. "Carmen A. Puliafito, MD, MBA, Former Dean of Keck School of Medicine of the University of Southern California, Joins Ophthotech as Chief of Strategic Development". Business Wire. April 28, 2016. Retrieved 17 July 2017.
  2. ^ Carmen Puliafito named new dean of the Keck School of Medicine. University of Southern California. Accessed February 2015.
  3. "About Carmen A. Puliafito". Retrieved 17 July 2017.
  4. USC Press Release. Dec 5 2007. USC Installs Dr. Carmen Puliafito as New Dean of the Keck School of Medicine
  5. Alex Philippidis (Nov 18, 2013). "25 Top-Paid Research University Leaders". Genetic Engineering & Biotechnology News. Accessed February 2015.
  6. Maamoon, Noorhan. "Dean of Keck School of Medicine of USC resigns". Daily Trojan. Retrieved 2016-04-03.
  7. http://www.chla.org/site/c.ipINKTOAJsG/b.5264283/
  8. ^ (May 2002). New Products. Optometry & Vision Science 79 (5): 279–280. Accessed February 2015.
  9. 2012: Williams & Fujimoto, Huang, Puliafito, Schuman, Swanson. Champalimaud Foundation. Accessed February 2015.
  10. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. (2005). Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112:1035–47.
  11. Rosenfeld PJ, Moshfegi AA, Puliafito CA. (2005). Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surgery, Lasers & Imaging 36: 331–5.
  12. Rich RM, Rosenfeld PJ, Puliafito CA, et al. (2006). Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26: 495–511.
  13. Moshfegi AA, Rosenfeld PJ, Puliafito CA, et al. (2006). Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 113: 2002–11.
  14. ^ "An overdose, a young companion, drug-fueled parties: The secret life of USC med school dean". Los Angeles Times. ISSN 0458-3035. Retrieved 2017-07-17.
Categories: